![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » European Commission Approves Anti-Epileptic Fycompa as Adjunct for Children
European Commission Approves Anti-Epileptic Fycompa as Adjunct for Children
![](https://www.fdanews.com/ext/resources/test/Drug-Images2/Eisai.gif?t=1434726928&width=430)
November 16, 2020
Eisai’s Fycompa (perampanel) has received approval from the European Commission as an adjunct treatment for partial-onset seizures in children 4 years and older, and for seizures in children 7 years and older with generalized epilepsy.
The approval was supported by positive results from two late-stage global trials that assessed patients for up to 41 weeks following treatment.
Pediatric epilepsy can pose a range of developmental problems for children, including neurocognitive, behavioral, social and psychiatric issues. In Europe, epilepsy affects an estimated 1 million children, with 100,000 new cases diagnosed annually.
Upcoming Events
-
21Oct